Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Expectations By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14, Zacks reports. The firm had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.10 million.

Coya Therapeutics Stock Performance

NASDAQ COYA traded up $0.21 during trading hours on Friday, reaching $6.68. The company's stock had a trading volume of 49,741 shares, compared to its average volume of 71,330. The stock has a market cap of $111.72 million, a PE ratio of -10.28 and a beta of 0.31. Coya Therapeutics has a fifty-two week low of $4.75 and a fifty-two week high of $10.24. The company's 50-day moving average is $6.33 and its two-hundred day moving average is $6.49.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday. D. Boral Capital reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.